Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 430 is a DNA-binding transcription factor of the C2H2-type zinc finger protein family, predicted to regulate gene expression through sequence-specific binding to RNA polymerase II cis-regulatory regions and DNA, with a role in substantia nigra development and possible involvement in cancer[1][2][3][4]. It is a nuclear protein, part of the most prevalent class of zinc finger-containing transcription factors, which are central to gene regulatory networks and implicated in both normal development and tumorigenesis[1][2][3][4]. No evidence currently indicates it is directly druggable, nor are there known drugs or clinical biomarkers specifically targeting ZNF430[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 430 (ZNF430).